CH574742A5 - - Google Patents

Info

Publication number
CH574742A5
CH574742A5 CH1062271A CH1062271A CH574742A5 CH 574742 A5 CH574742 A5 CH 574742A5 CH 1062271 A CH1062271 A CH 1062271A CH 1062271 A CH1062271 A CH 1062271A CH 574742 A5 CH574742 A5 CH 574742A5
Authority
CH
Switzerland
Application number
CH1062271A
Inventor
Zaffaroni Alejandro
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ZA714095A external-priority patent/ZA714095B/xx
Application filed by Alza Corp filed Critical Alza Corp
Publication of CH574742A5 publication Critical patent/CH574742A5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
CH1062271A 1969-04-01 1971-07-19 CH574742A5 (cs)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81211669A 1969-04-01 1969-04-01
US00042786A US3854480A (en) 1969-04-01 1970-06-02 Drug-delivery system
ZA714095A ZA714095B (en) 1969-04-01 1971-06-22 Bandage for administering drugs
FR7123703A FR2143564A1 (en) 1969-04-01 1971-06-29 Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates

Publications (1)

Publication Number Publication Date
CH574742A5 true CH574742A5 (cs) 1976-04-30

Family

ID=37734020

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1062271A CH574742A5 (cs) 1969-04-01 1971-07-19

Country Status (4)

Country Link
US (1) US3854480A (cs)
CH (1) CH574742A5 (cs)
DE (1) DE2135533C3 (cs)
FR (1) FR2143564A1 (cs)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144486A3 (en) * 1983-04-27 1986-05-14 Lohmann Gmbh & Co Kg Controlled-release drugsystem and process for preparing it
AT395815B (de) * 1981-06-29 1993-03-25 Alza Corp Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut

Families Citing this family (603)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4016251A (en) * 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4014987A (en) * 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4057619A (en) * 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4186745A (en) * 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
DE2650306A1 (de) * 1976-11-02 1978-05-03 Merck Patent Gmbh Antibakteriell wirkender wundverband und verfahren zu seiner herstellung
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4460367A (en) * 1977-06-09 1984-07-17 Alza Corporation Device containing biocide producing paraformalde and an acid
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
EP0009517A1 (en) * 1978-10-04 1980-04-16 THE PROCTER & GAMBLE COMPANY Vaginal contraceptive
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
GB2047543B (en) * 1978-12-06 1983-04-20 Svedman Paul Device for treating tissues for example skin
US4308867A (en) * 1979-03-23 1982-01-05 Roseman Theodore J Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals
DE3068649D1 (en) * 1979-03-23 1984-08-30 Upjohn Co Medicated device for controlled drug release
US4237888A (en) * 1979-03-23 1980-12-09 The Upjohn Company Two-membrane medicated device for rate-controlled administration of prostaglandins
EP0021504B1 (en) * 1979-06-25 1984-10-03 THE PROCTER & GAMBLE COMPANY Article for use as catheter or the like
US4392848A (en) * 1979-06-25 1983-07-12 The Procter & Gamble Company Catheterization
US4343788A (en) * 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
US4479795A (en) * 1979-06-29 1984-10-30 The Procter & Gamble Company Antimicrobial polymer compositions
PH25589A (en) * 1979-09-12 1991-08-08 Lilly Co Eli Device for drug celivery to ruminants
US4326510A (en) * 1979-11-20 1982-04-27 World Health Organization Barrier contraceptive torus
JPS5777617A (en) * 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
FR2512651B1 (fr) * 1981-06-24 1986-01-17 Pere Lahaille Jeanne Produits anti-rides
US5069671A (en) * 1981-07-13 1991-12-03 Alza Corporation Intravenous medication
US4985017A (en) * 1981-07-13 1991-01-15 Alza Corporation Parenteral therapeutical system comprising drug cell
US4511353A (en) * 1981-07-13 1985-04-16 Alza Corporation Intravenous system for delivering a beneficial agent
US4790820A (en) * 1981-07-13 1988-12-13 Alza Corporation Parenteral agent dispensing equipment with drug releasing member
US4973307A (en) * 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US4432756A (en) * 1981-11-27 1984-02-21 Alza Corporation Parenteral controlled therapy
US4740201A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
USRE34365E (en) * 1981-07-13 1993-08-31 Intravenous system for delivering a beneficial agent
US4994031A (en) * 1981-07-13 1991-02-19 Alza Corporation Intravenous system for delivering a beneficial agent
US4857052A (en) * 1981-07-13 1989-08-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4525162A (en) * 1981-07-31 1985-06-25 Alza Corporation Parenteral controlled delivery
US4871360A (en) * 1981-07-31 1989-10-03 Alza Corporation System for intravenous delivery of a beneficial drug at a regulated rates
US4740197A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent via polymer delivery
US4740103A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4741735A (en) * 1981-10-09 1988-05-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4740199A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4586922A (en) * 1981-10-09 1986-05-06 Alza Corporation Intravenous system for delivering a beneficial agent
US4741734A (en) * 1981-10-09 1988-05-03 Alza Corporation Releasing means for adding agent using releasing means to IV fluid
US4740200A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4479794A (en) * 1981-11-27 1984-10-30 Alza Corporation System for intravenous therapy
US4583981A (en) * 1981-11-27 1986-04-22 Alza Corporation Parenteral controlled therapy, using a porous matrix with parenteral agent
US4552556A (en) * 1981-11-27 1985-11-12 Alza Corporation Parenteral controlled therapy
US4479793A (en) * 1981-11-27 1984-10-30 Alza Corporation Parenteral administration using drug delivery device
US4493702A (en) * 1981-11-27 1985-01-15 Alza Corporation Parenteral administration using osmotically motivated delivery system
US4579553A (en) * 1981-11-27 1986-04-01 Alza Corporation Parenteral controlled therapy
US4548599A (en) * 1981-11-27 1985-10-22 Alza Corporation Parenteral controlled therapy
US4484909A (en) * 1981-11-27 1984-11-27 Alza Corporation Parenteral therapy using solid drug
US4908019A (en) * 1982-05-24 1990-03-13 Alza Corporation Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
US4664650A (en) * 1982-05-24 1987-05-12 Alza Corporation Apparatus for parenteral infusion of fluid containing beneficial agent
US4515585A (en) * 1982-05-24 1985-05-07 Alza Corporation System for parenteral administration of agent
CA1206049A (en) * 1982-09-30 1986-06-17 Paul E. Michelson Osmotic device for physiological applications
US4709996A (en) * 1982-09-30 1987-12-01 Michelson Paul E Fluid lens
FR2534140B1 (fr) * 1982-10-12 1986-01-31 Fournier Laboratoires Nouveau dispositif pour l'administration percutanee de medicaments
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
FR2538247B1 (fr) * 1982-12-23 1986-05-23 Pere Lahaille Jeanne Pastille anti-rides et/ou traitant la peau
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4623329A (en) * 1983-12-15 1986-11-18 The Procter & Gamble Company Drainage and infusion catheters having a capillary sleeve forming a reservoir for a fluid antimicrobial agent
ATE62414T1 (de) * 1984-01-28 1991-04-15 Roshdy Ismail Mittel zur behandlung von herzerkrankungen.
EP0154598B1 (de) * 1984-03-07 1991-12-27 Wolfgang Dr. Holz Verfahren zur Verabreichung von Medikamenten od. dgl. an in Wasserbehältern gehaltene Tiere, insbesondere Fische
US4511352A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system with in-line container
US4596555A (en) * 1984-05-14 1986-06-24 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4511351A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4618487A (en) * 1984-07-06 1986-10-21 Alza Corporation Device for administering calcium ascorbate
DE3447833A1 (de) * 1984-12-29 1986-07-10 Allan Gerhard 8047 Karlsfeld Frühauf Tuch o.dgl. mit einen wirkstoff enthaltenden mikrokapseln
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
US5820876A (en) 1986-08-28 1998-10-13 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
US6139868A (en) * 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6117448A (en) * 1986-08-28 2000-09-12 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6126963A (en) 1986-08-28 2000-10-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
JPH0794384B2 (ja) * 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
US5322695A (en) * 1987-01-09 1994-06-21 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
EP0274863B1 (en) * 1987-01-09 1994-06-15 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems
DE3823070A1 (de) * 1988-07-07 1990-02-22 Kettelhack Riker Pharma Gmbh Selbstklebendes heftpflaster
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
DE3844247A1 (de) * 1988-12-29 1990-07-12 Minnesota Mining & Mfg Vorrichtung, insbesondere pflaster zum transdermalen verabreichen eines medikaments
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648143B1 (fr) * 1989-06-08 1991-09-06 Rhone Poulenc Chimie Composition comprenant un copolymere silicone thermoplastique et un compose de l'iode, utilisable apres sa mise en forme, pour le traitement des eaux
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US6264638B1 (en) 1989-12-07 2001-07-24 Ultrafem, Inc. Intravaginal drug delivery system and discharge collection device
US5295984A (en) 1989-12-07 1994-03-22 Ultrafem, Inc. Vaginal discharge collection device and intravaginal drug delivery system
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
WO1991018570A1 (en) * 1990-06-01 1991-12-12 Robertson, Dale, N. Therapeutically effective topical application of st1435
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
DE59203307D1 (de) 1991-06-10 1995-09-21 Lohmann Therapie Syst Lts Nitroglycerin-pflaster und verfahren zu seiner herstellung.
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5827245A (en) * 1992-07-16 1998-10-27 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising the active subtance 17-β-Estradiol (Anhydrous)
DE4223360C1 (cs) * 1992-07-16 1993-04-08 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4328217C2 (de) * 1993-08-21 1996-01-11 Lohmann Therapie Syst Lts Therapeutisches System zur Behandlung der Psoriasis
JPH09504719A (ja) * 1993-11-03 1997-05-13 クラリオン、ファーマシューティカルズ、インコーポレイテッド 止血パッチ
US5762955A (en) 1994-02-04 1998-06-09 Smith; Stephen Jay Method for application and maintenance of medication on body tissue
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5531681A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
TW592729B (en) * 1995-04-06 2004-06-21 Janssen Pharmaceutica Nv Rate-controlled transdermal administration of risperidone
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
KR20000022465A (ko) 1996-07-03 2000-04-25 세바스티안 레슬리 제이. 탄성중합체 물질을 제작하기 위한 방법 및장치.
US20030093143A1 (en) * 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
EP2305235A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
ATE395931T1 (de) 1998-07-15 2008-06-15 Brigham & Womens Hospital Polysaccharid-impfstoff gegen staphylokokken infektionen
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
US6056976A (en) * 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
CA2360396A1 (en) 1998-12-30 2000-07-13 Andrew M. Scharenberg Characterization of a calcium channel family
DE19912477A1 (de) * 1999-03-19 2000-09-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System und Verfahren zu seiner Herstellung
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
CA2372079A1 (en) 1999-05-05 2000-11-09 Aaron H. Leeman Novel catechols as antimicrobial agents
JP2002543129A (ja) 1999-05-05 2002-12-17 メルク エンド カムパニー インコーポレーテッド 抗微生物剤としての新規なプロリン類
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
HU229085B1 (en) 1999-07-02 2013-07-29 Lohmann Therapie Syst Lts Microreservoir system on the basis of polysiloxanes and ambiphilic solvents
EP2267029B1 (en) 1999-09-03 2016-06-15 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
EP1225901A2 (en) * 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
DE19949202A1 (de) * 1999-10-13 2001-05-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure
DE19949252B4 (de) * 1999-10-13 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines superfiziellen therapeutischen Systems zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen und Verfahren zu seiner Herstellung
IL150223A0 (en) 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides and pharmaceutical compositions containing the same
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
WO2001078709A2 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DK1296714T3 (da) 2000-06-22 2009-12-07 Coley Pharm Gmbh Kombination af CpG og antistoffer, der er rettet mod CD19, CD20, CD22 eller CD40 til behandling eller forebyggelse af kræft
US6696488B2 (en) 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
US7858331B2 (en) * 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
ATE481640T1 (de) 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
ATE398175T1 (de) 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
KR20080036661A (ko) 2000-12-18 2008-04-28 큐비스트 파마슈티컬즈 인코포레이티드 정제된 리포펩티드의 제조 방법
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7923055B2 (en) 2001-05-11 2011-04-12 Exogenesis Corporation Method of manufacturing a drug delivery system
CA2449175A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
DK1455593T3 (da) 2001-10-06 2013-08-26 Merial Ltd Fremgangsmåder og sammensætninger til fremme af vækst og medfødt immunitet hos unge dyr
EP1441763A2 (en) * 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20030049698A1 (en) * 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US7375088B2 (en) * 2003-01-21 2008-05-20 Thallion Pharmaceuticals Inc. Polyene polyketides, processes for their production and their use as a pharmaceutical
US7358241B2 (en) * 2003-01-21 2008-04-15 Thallion Pharmaceuticals, Inc. Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
CA2466340C (en) * 2003-01-21 2007-07-10 Ecopia Biosciences Inc. Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
DE102004002243A1 (de) * 2003-02-07 2004-09-16 Trikon Technologies Limited, Newport Elektrostatische Klemmhalterung für dünne Wafer in einer Vakuumkammer zur Plasmabearbeitung
ES2380147T3 (es) 2003-02-11 2012-05-09 Shire Human Genetic Therapies, Inc. Diagnóstico y tratamiento de deficiencia múltiple de sulfatasas y otras usando una enzima generadora de formilglicina(FGE)
EP1596871A4 (en) 2003-02-28 2006-08-23 Drew M Pardoll T-CELL REGULATION
WO2004078943A2 (en) * 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
CA2467249C (en) * 2003-05-13 2005-03-22 Ecopia Biosciences Inc. Polyene polyketides, processes for their production and their use as pharmaceuticals
TWI336627B (en) 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
CA2470935A1 (en) * 2003-06-13 2004-12-13 Ecopia Biosciences Inc. Polyene oxazoles and processes for their preparation
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
JP2007524616A (ja) * 2003-06-20 2007-08-30 ヴァイラル・ジェノミックス・インコーポレーテッド Ｈｉｖを処置するための組成物および方法
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
EP1648286B1 (en) 2003-07-12 2017-12-20 Accelerate Diagnostics, Inc. Sensitive and rapid biodetection
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
EP1656555B1 (en) 2003-08-20 2012-03-21 Alere San Diego, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
EP1539962A4 (en) * 2003-09-11 2006-12-27 Ecopia Biosciences Inc POLYENPOLYKETIDES AND METHODS FOR THEIR PREPARATION
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
CA2552351A1 (en) 2004-01-30 2005-09-09 Dana-Farber Cancer Institute, Inc. Method for determination and quantification of radiation or genotoxin exposure
EP1722823A2 (en) * 2004-02-27 2006-11-22 Antisense Pharma GmbH Pharmaceutical composition
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7504086B2 (en) * 2004-03-31 2009-03-17 Canon Kabushiki Kaisha Structure and method for releasing substance therefrom
US7786255B2 (en) 2004-04-21 2010-08-31 The Bringham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
PT1629844E (pt) 2004-07-13 2007-10-17 Bayer Schering Pharma Oy Sistema de distribuição a longo prazo com distribuição súbita inicial controlada
US7456209B2 (en) * 2004-07-15 2008-11-25 Tetralogic Pharmaceuticals Corporation IAP binding compounds
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
EP2338994B1 (en) 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
JP5635726B2 (ja) * 2004-09-14 2014-12-03 ミネルバ バイオテクノロジーズ コーポレーション 癌の診断方法及び治療方法
WO2006034454A1 (en) * 2004-09-23 2006-03-30 The Trustees Of The University Of Princeton Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
AU2005294165B2 (en) 2004-10-06 2012-02-02 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006047891A1 (en) * 2004-11-08 2006-05-11 Ecopia Biosciences Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
WO2006052991A2 (en) 2004-11-11 2006-05-18 The General Hosptial Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
EP1851200B1 (en) 2005-02-25 2014-01-15 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
EP1861096B1 (en) 2005-03-07 2018-12-26 The University of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006105448A2 (en) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
EP2407178A2 (en) 2005-04-19 2012-01-18 Eli Lilly and Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
ZA200709237B (en) 2005-05-05 2009-04-29 Antisense Pharma Gmbh Dosage of oligonucleotides
US7763604B2 (en) * 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2547866C (en) * 2005-06-02 2008-08-12 Ecopia Biosciences Inc. Farnesyl dibenzodiazepinone formulation
CN101198324B (zh) * 2005-06-16 2011-06-08 欧洲凯尔特公司 用于改进剂型的大麻素活性药物成分
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
KR101502920B1 (ko) 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
AU2006270066A1 (en) 2005-07-19 2007-01-25 University Of Tennessee Research Foundation LPA2 receptor agonist inhibitors of CFTR
CA2616537A1 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20070042428A1 (en) * 2005-08-09 2007-02-22 Stacy Springs Treatment of proliferative disorders
ES2400091T3 (es) 2005-08-11 2013-04-05 Massachusetts Institute Of Technology Dispositivo de suministro de fármacos intravesical y método
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
WO2007027559A2 (en) 2005-08-29 2007-03-08 Shashoua Victor E Neuroprotective and neurorestorative methods and compositions
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CA2630738C (en) 2005-11-25 2013-09-03 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
WO2007064997A2 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
KR101141333B1 (ko) 2006-06-20 2012-05-23 트랜스진 에스.에이. 재조합 바이러스 백신
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
AR063943A1 (es) 2006-07-24 2009-03-04 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20100092480A1 (en) * 2006-10-13 2010-04-15 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
EP2099906B1 (en) 2007-01-05 2014-03-12 Massachusetts Institute of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
JP2010515464A (ja) * 2007-01-11 2010-05-13 イエール・ユニバーシテイ Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
AU2014202051C1 (en) * 2007-02-06 2021-04-22 Columbia Laboratories (Bermuda) Limited Progesterone for the treatment of preterm birth
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
US20090081237A1 (en) 2007-03-12 2009-03-26 Dana-Farber Cancer Institute Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
CN101801979A (zh) 2007-03-29 2010-08-11 普罗热尼奇制药公司 (r)-n-溴化甲基纳曲酮的晶体形式及其用途
EP3064503A1 (en) 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
WO2008121860A1 (en) 2007-03-29 2008-10-09 Wyeth Peripheral opioid receptor and antagonists and uses thereof
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
CA2718573C (en) 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
CN101678098A (zh) * 2007-05-17 2010-03-24 科勒制药集团公司 具有免疫刺激效力的a类寡核苷酸
CN101711287B (zh) 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
US8524444B2 (en) 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
US20100291219A1 (en) * 2007-06-21 2010-11-18 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
JP2010536335A (ja) 2007-08-13 2010-12-02 ファイザー・インク 活性が改善した組合せモチーフ免疫賦活性オリゴヌクレオチド
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
ES2481454T3 (es) * 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
PL2359807T3 (pl) 2008-02-04 2017-12-29 Ferring B.V. Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US20090233858A1 (en) * 2008-02-26 2009-09-17 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
WO2009111375A2 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
US20110191868A1 (en) 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US20110076296A1 (en) 2008-04-25 2011-03-31 Innate Pharma S.A. TLR3 Agonist Compositions
JP2011519951A (ja) * 2008-05-07 2011-07-14 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ｍｉＲＮＡによる薬物治療の増強
WO2009151561A2 (en) 2008-06-12 2009-12-17 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
WO2010011347A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
CN102176931B (zh) * 2008-08-09 2015-03-04 麻省理工学院 治疗男性泌尿生殖组织和外周组织的可植入药物递送设备和方法
EP2328412A4 (en) 2008-09-17 2012-03-14 Tetralogic Pharm Corp IPA INHIBITORS
EP2331103A1 (en) * 2008-09-22 2011-06-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
WO2010036938A2 (en) * 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN102272290B (zh) 2008-10-09 2018-08-14 米纳瓦生物技术公司 用于在细胞中诱导多能性的方法
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
US8414912B2 (en) * 2008-12-11 2013-04-09 Massachusetts Institute Of Technology Contact lens drug delivery device
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
CN102325787B (zh) 2008-12-22 2014-05-28 丘比斯特药物股份有限公司 治疗革兰氏阳性感染的新的抗菌剂
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8343912B2 (en) * 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
AU2010238723A1 (en) 2009-04-23 2011-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
CA2760547C (en) 2009-04-30 2020-03-24 Karlyne Reilly Schweinfurthins and uses thereof
WO2010130374A1 (en) 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
JP2012528858A (ja) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Ｏ−ＧｌｃＮＡｃ転移酵素阻害剤およびその使用
IN2012DN00352A (cs) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CA2765511C (en) 2009-06-16 2015-05-12 The Regents Of The University Of Michigan Nanoemulsion vaccines
EA023156B1 (ru) 2009-06-26 2016-04-29 ТАРИС Биомедикал ЛЛК Устройство для доставки лекарств
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011011092A1 (en) 2009-07-22 2011-01-27 University Of Massachusetts Methods and compositions to reduce oxidative stress
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
EP2340308B1 (en) 2009-07-30 2014-12-24 ISARNA Therapeutics GmbH Combination of dacarbazine and an inhibitor of the TGF-beta system
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
HRP20170404T1 (hr) 2009-08-18 2017-05-19 Ventirx Pharmaceuticals, Inc. SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
PL2467380T3 (pl) 2009-08-18 2017-09-29 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora typu Toll
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2010301042B2 (en) 2009-10-01 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2817779T3 (es) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
CA2805267C (en) 2010-05-04 2019-07-30 The Brigham And Women's Hospital, Inc. Detection and treatment of fibrosis
CA2798084A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
DE102010050242A1 (de) 2010-10-30 2012-05-03 Schott Ag Wirkstoffverpackung
SG190794A1 (en) 2010-11-18 2013-07-31 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
AU2011336650B2 (en) 2010-12-01 2016-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
UY33821A (es) 2010-12-22 2012-07-31 Bayer Animal Health Gmbh Respuesta inmune potenciada en la especie bovina
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
PT2663555T (pt) 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
CN103459598B (zh) 2011-02-03 2016-08-10 米尔纳医疗股份有限公司 Mir-124的合成模拟物
MX342927B (es) 2011-02-03 2016-10-19 Mirna Therapeutics Inc Mimeticos sinteticos de mir-34.
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
EP2683831B1 (en) 2011-03-07 2015-09-23 Accelerate Diagnostics, Inc. Rapid cell purification systems
WO2012125623A2 (en) 2011-03-14 2012-09-20 Ludwig Institute For Cancer Research Ltd. Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
JP6196163B2 (ja) 2011-03-17 2017-09-13 ミネルバ バイオテクノロジーズ コーポレーション 多能性幹細胞を作製する方法
PT2694549T (pt) 2011-04-08 2018-11-22 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização do mesmo para o tratamento de cancro
CN105148285B (zh) 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
CA2837207A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
US9937335B2 (en) * 2011-06-06 2018-04-10 Oak Crest Institute Of Science Drug delivery device employing wicking release window
WO2012174064A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US10765654B2 (en) 2011-07-19 2020-09-08 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
CA2844197A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolina Healthcare System Treatment of fibrosis using microrna-19b
IN2014KN00948A (cs) 2011-10-04 2015-08-21 Janus Biotherapeutics Inc
JP6466170B2 (ja) 2011-10-17 2019-02-06 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞の増殖及び誘導用の培地
AU2012325341B2 (en) 2011-10-19 2017-01-05 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
BR112014012997A2 (pt) 2011-11-30 2017-06-13 Bikam Pharmaceuticals Inc ligantes que se ligam à opsina, composições e métodos de uso
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2794657B1 (en) 2011-12-19 2017-10-11 Xoma (Us) Llc Methods for treating acne
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
JP6684490B2 (ja) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
JP2015514095A (ja) 2012-03-30 2015-05-18 キュービスト ファーマシューティカルズ， インコーポレイテッド １，３，４−オキサジアゾールおよび１，３，４−チアジアゾールβ−ラクタマーゼ阻害剤
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
CN110511278B (zh) 2012-05-07 2024-08-09 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
CA2878829A1 (en) 2012-07-11 2014-01-16 University Of Vermont And State Agricultural College Methylation-controlled j protein (mcj) for treatment of liver disease and altering mitochondrial metabolism
KR101835401B1 (ko) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 키랄 핵산 어쥬번트
EP2887942A4 (en) 2012-08-21 2016-08-31 Genesys Res Inst COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ANTHRACYCLIN-INDUCED CARDIOTOXICITY
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
WO2014055941A2 (en) 2012-10-04 2014-04-10 Pappalardo Juan Sabastian Compounds and methods for targeted immune system delivery
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
WO2014093726A1 (en) 2012-12-12 2014-06-19 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating portal hypertension
WO2014093711A1 (en) 2012-12-12 2014-06-19 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
EP2971166B1 (en) 2013-03-14 2021-05-19 Children's Medical Center Corporation Psap peptide for treating cd36 expressing cancers
CA2903164C (en) 2013-03-15 2024-06-11 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
KR102774944B1 (ko) 2013-03-15 2025-02-27 트러스티즈 오브 터프츠 칼리지 저분자량 실크 조성물 및 안정화 실크 조성물
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
JP2016522165A (ja) 2013-04-04 2016-07-28 イエオ−イスティトゥート・エウロペオ・ディ・オンコロジア・エッセ・エッレ・エッレ 胸腺間質性リンパ球新生因子フラグメント及びその使用
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
EA036275B1 (ru) 2013-06-25 2020-10-21 Дзе Уолтер Энд Элиза Хол Инститьют Оф Медикал Рисерч Способ лечения внутриклеточной инфекции
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
BR112016002646B1 (pt) 2013-08-19 2022-01-25 Taris Biomedical Llc Dispositivo intravesical de entrega de fármaco
EP3035849B1 (en) 2013-08-21 2019-07-31 Senseonics, Incorporated Drug elution for in vivo protection of bio-sensing analytes
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
JP6734774B2 (ja) 2013-10-15 2020-08-05 ザ スクリプス リサーチ インスティテュート ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
KR101977449B1 (ko) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 알부민 변이체 및 이의 용도
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
SG11201604565WA (en) 2013-12-06 2016-07-28 Us Health Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
WO2015095406A1 (en) 2013-12-18 2015-06-25 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
SG10201805933TA (en) 2013-12-24 2018-08-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JP6772065B2 (ja) 2014-02-28 2020-10-21 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 免疫賦活プラスミド
WO2015142865A2 (en) 2014-03-17 2015-09-24 Massachusetts Institute Of Technology Metakaryocidal treatments
US10646541B2 (en) 2014-03-26 2020-05-12 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
WO2015161230A1 (en) 2014-04-19 2015-10-22 Massachusetts Institute Of Technology Methods of reducing kinase inhibitor resistance
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10272019B2 (en) 2014-05-09 2019-04-30 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
CN106456377A (zh) * 2014-05-30 2017-02-22 纺织品技术股份有限公司 药物递送系统以及相关使用方法
KR102391761B1 (ko) * 2014-06-26 2022-04-27 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016029077A1 (en) 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2016044383A1 (en) 2014-09-17 2016-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016046847A1 (en) 2014-09-23 2016-03-31 Council Of Scientific & Industrial Research Metal embedded hydrophilic polymer for drug delivery applications
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
EP3212173A4 (en) * 2014-10-30 2018-06-20 Textile-Based Delivery, Inc. Delivery systems
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
EP3258953B1 (en) 2015-02-18 2023-07-05 University of Vermont and State Agricultural College Mcj polypeptides for use in treating cancer
EP3268034A4 (en) 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
US10023895B2 (en) 2015-03-30 2018-07-17 Accelerate Diagnostics, Inc. Instrument and system for rapid microogranism identification and antimicrobial agent susceptibility testing
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3708680B8 (en) 2015-04-15 2023-08-30 University of Massachusetts Compositions and methods for xi chromosome reactivation
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
US10844392B2 (en) 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP3831844B1 (en) 2015-06-26 2024-03-13 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
WO2017004142A1 (en) 2015-06-29 2017-01-05 Children's Medical Center Corporation Treatment for myopathy
CN108136005A (zh) 2015-07-10 2018-06-08 佛蒙特大学及州农业学院 用于治疗药物诱导的疾病和病症的mcj抑制剂
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
KR20180039162A (ko) 2015-08-20 2018-04-17 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 간 질환 및 병태를 치료하기 위한 방법 및 조성물
US11819554B2 (en) 2015-09-17 2023-11-21 University Of Massachusetts Compositions and methods for modulating FMR1 expression
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
KR20180099887A (ko) 2016-01-20 2018-09-05 더 스크립스 리서치 인스티튜트 Ｒｏｒ2 항체 조성물 및 관련 방법
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
WO2017143042A2 (en) 2016-02-16 2017-08-24 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP7197078B2 (ja) 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
MX2018012719A (es) 2016-04-19 2019-05-30 Us Health Ram negativas para tratar la dermatitis atopica.
EP3454891A4 (en) 2016-05-10 2019-12-25 The Regents of The University of Michigan EMULSION ADJUVANS FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION
US20190391152A1 (en) 2016-05-16 2019-12-26 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
WO2017205747A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
US20190201414A1 (en) 2016-07-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
TWI759317B (zh) 2016-07-26 2022-04-01 德商拜耳動物保健有限公司 牛物種中增加的生育力
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
EP3535588A4 (en) 2016-11-07 2020-09-16 University of Massachusetts THERAPEUTIC TARGET MOLECULES FOR FACIO-CAPULOHUMERAL MUSCLE DYSTROPHY
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
CN110691973B (zh) 2017-04-25 2024-11-29 普罗瑟拉生物公司 用于定量间α抑制剂蛋白的方法
EP3615023B1 (en) 2017-04-25 2023-06-21 Ischemix LLC Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
CA3069809A1 (en) 2017-07-14 2019-01-17 University Of Massachusetts Methods and compositions for treating inflammation
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
WO2019030240A1 (en) 2017-08-07 2019-02-14 Nbe-Therapeutics Ag ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
US11103460B2 (en) 2017-08-07 2021-08-31 Board Of Regents, The University Of Texas System Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ ワクチン分子
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
KR102718550B1 (ko) 2017-12-29 2024-10-17 락손 메디칼 아게 약물 전달 시스템을 제조하기 위한 방법
WO2019129360A1 (en) 2017-12-29 2019-07-04 Laxxon Medical Ag Drug delivery system
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
KR20210006905A (ko) 2018-04-09 2021-01-19 체크메이트 파마슈티칼스 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
EP4070790A1 (en) 2018-04-19 2022-10-12 Tvardi Therapeutics, Inc. Stat3 inhibitors
KR20210013080A (ko) 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
CA3110250A1 (en) 2018-08-22 2020-02-27 Bacainn Therapeutics, Ltd. Cyclosporine compositions and methods of use
CN113164552B (zh) 2018-10-04 2025-06-06 新泽西州立罗格斯大学 使用神经介素肽减少2型细胞因子介导的炎症的方法
US11266617B2 (en) 2018-10-16 2022-03-08 Massachusetts Institute Of Technology Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
CN112912497B (zh) 2018-10-19 2024-01-12 德克萨斯州大学系统董事会 工程化长散在元件(line)转座子及其使用方法
CN113660934A (zh) 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
JOP20210194A1 (ar) 2019-01-18 2023-01-30 Janssen Biotech Inc مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها
AU2020215177A1 (en) 2019-01-30 2021-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
WO2020191183A1 (en) 2019-03-21 2020-09-24 Mitotherapeutix Llc Multivalent ligand clusters for targeted delivery of therapeutic agents
JP2022526194A (ja) 2019-04-10 2022-05-23 エレベートバイオ テクノロジーズ，インコーポレイテッド Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
BR112021023411A2 (pt) 2019-05-22 2022-02-01 Massachusetts Inst Technology Composições e métodos de rna circular
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
MX2022001058A (es) 2019-07-26 2022-02-14 Janssen Biotech Inc Receptor de antigeno quimerico (car) anti-hk2.
AU2020322222A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
US20220280656A1 (en) 2019-07-31 2022-09-08 Yale University Compositions and methods for treating sickle cell disease
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
US20210047423A1 (en) 2019-08-16 2021-02-18 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
PE20221273A1 (es) 2019-11-18 2022-09-01 Janssen Biotech Inc Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
EP4107267A1 (en) 2020-02-21 2022-12-28 Mitotherapeutix LLC Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
UY39130A (es) 2020-03-13 2021-09-30 Janssen Biotech Inc Materiales y métodos para la unión de lectina tipo ig de unión a ácido siálico
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
CA3182275A1 (en) 2020-05-08 2021-11-11 Georgiamune Llc Akt3 modulators
AU2021276410A1 (en) 2020-05-19 2023-01-19 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
JP2023537470A (ja) 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
WO2022081895A1 (en) 2020-10-16 2022-04-21 University Of Georgia Research Foundation, Inc. Glycoconjugates
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
KR20230160314A (ko) 2021-03-24 2023-11-23 얀센 바이오테크 인코포레이티드 Cd22 및 cd79b를 표적화하는 항체
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
JP2024517759A (ja) 2021-04-28 2024-04-23 ミノトール セラピューティクス インコーポレイテッド ヒト化キメラウシ抗体および使用方法
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
CN117794946A (zh) 2021-06-09 2024-03-29 斯克利普斯研究所 长效双重gip/glp-1肽缀合物及使用方法
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
CA3228786A1 (en) 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd25 antibody
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
TW202334080A (zh) 2021-11-08 2023-09-01 美商歐納醫療公司 用於遞送環狀聚核苷酸之脂質奈米粒子組合物
MX2024005862A (es) 2021-11-16 2024-07-10 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt).
MX2024006348A (es) 2021-11-29 2024-06-11 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina del virus de la hepatitis b (vhb).
EP4453212A1 (en) 2021-12-23 2024-10-30 University of Massachusetts Therapeutic treatment for fragile x-associated disorder
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
US20250289903A1 (en) 2022-04-29 2025-09-18 Purinnomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
EP4532731A2 (en) 2022-05-30 2025-04-09 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024039376A1 (en) 2022-08-18 2024-02-22 Elanco Us Inc. Method for improving growth performance in feedlot cattle
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
EP4622984A1 (en) 2022-11-21 2025-10-01 Northeastern University Click chemistry ligand
AU2023404700A1 (en) 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025059689A1 (en) 2023-09-16 2025-03-20 University Of Massachusetts Compositions and methods for promoting the generation of pharyngeal foregut endoderm and its derivatives
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
BE636865A (cs) * 1962-08-31
US3518340A (en) * 1968-04-15 1970-06-30 Dow Corning Method of forming silicone rubber drug carriers
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395815B (de) * 1981-06-29 1993-03-25 Alza Corp Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut
EP0144486A3 (en) * 1983-04-27 1986-05-14 Lohmann Gmbh & Co Kg Controlled-release drugsystem and process for preparing it

Also Published As

Publication number Publication date
FR2143564B1 (cs) 1974-04-05
DE2135533C3 (de) 1981-02-12
US3854480A (en) 1974-12-17
FR2143564A1 (en) 1973-02-09
DE2135533B2 (de) 1980-06-04
DE2135533A1 (de) 1973-02-01

Similar Documents

Publication Publication Date Title
FR2143564B1 (cs)
CS148810B1 (cs)
AU465413B2 (cs)
AU429630B2 (cs)
CS153545B2 (cs)
AU450150B2 (cs)
AU442375B2 (cs)
AU427401B2 (cs)
AU470301B1 (cs)
AU438128B2 (cs)
AU428129B2 (cs)
AU442535B2 (cs)
AU417208B2 (cs)
AU442380B2 (cs)
AU425297B2 (cs)
AU442322B2 (cs)
AU442285B2 (cs)
AU470661B1 (cs)
AU428074B2 (cs)
AU442554B2 (cs)
AU442538B2 (cs)
AU428131B2 (cs)
CS153549B2 (cs)
AU4540468A (cs)
AU5228269A (cs)

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased